Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Starting soon · Not applicable

Conditions studied: Advanced Solid Tumor

In brief

The purpose of this study is to evaluate the safety, immunogenicity and preliminary efficacy of engineered dendritic cells（eDCs）loaded with mKRAS antigen (CAT-101) alone or in combination with Tislelizumab (anti-PD-1 monoclonal antibody) among participants with KRAS-G12C/D/R/V mutated advanced pancreatic cancer and other solid tumors.

Key facts

Study ID

NCT07396090

Run by

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

People needed

13

Starts

2026-01-20

Expected to finish

2026-12-31

Last updated by the study team

2026-02-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.